Tag Archives: Could

AMAG wins FDA nod for Vyleesi. Could it be the ‘female Viagra’ that Addyi never was?

Valeant, now Bausch Health, paid $ 1 billon in 2015 for Sprout Pharmaceuticals’ female libido drug Addyi, only to sell it back in 2017. Now as the drug is still nowhere near the blockbuster status Valeant once touted, a rival has arrived. The FDA late Friday approved AMAG Pharmaceuticals’ Vyleesi (bremelanotide) to treat premenopausal women with… Read More »

Novartis could settle for $1B as part of federal kickback lawsuit: report

Six years after federal prosecutors first targeted Novartis for an alleged kickback scheme involving $ 10,000 dinners and fishing trips for doctors, signs pointed to the Swiss drugmaker finally having its day in court. Now, it looks like that may not happen. Novartis could be approaching a billion-dollar settlement with the U.S. government as part… Read More »

Newly recognised form of dementia could now be easier to diagnose

Multiple types of dementia affect brain functionALFRED PASIEKA/SCIENCE PHOTO LIBRARY By New Scientist staff and Press Association Researchers have published guidelines for diagnosing a newly recognised form of dementia that progresses more slowly than Alzheimer’s disease and tends to affect people near the end of their lives. Unlike people who have Alzheimer’s disease, people with… Read More »

Medical News Today: New treatment under trial could restore brain cells in Parkinson's

A series of clinical trials have tested an experimental treatment for Parkinson’s disease that uses a novel approach: administering the drug straight into the brain via implanted ports. The leading researchers believe this may be a “breakthrough” therapeutic strategy for neurological conditions. Newly trialed therapy could launch a fresh chapter in the treatment of Parkinson’s… Read More »